Spyre Therapeutics

Spyre Therapeutics

Yahoo Finance • 10 days ago

Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says

Spyre Therapeutics' (SYRE) combination therapy approach for inflammatory bowel disease gained furthe PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 29 days ago

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled... Full story

Yahoo Finance • last month

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

DelveInsight Business Research LLP The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokima... Full story

Yahoo Finance • last month

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart's Histopathology Index score at Week... Full story

Yahoo Finance • 2 months ago

Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.

Boston Scientific Corporation (NYSE:BSX) fell 2.3% in early trading on September 8, 2026, after disclosing that an August 25 cyberattack disrupted manufacturing and shipping. The company stated it is unlikely to meet its previously issued... Full story

Yahoo Finance • 2 months ago

Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.

Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen,... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for Spyre Therapeutics (SYRE). Shares have lost about 16.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue le... Full story

Yahoo Finance • 2 months ago

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre Therapeutics SYRE has built a broad clinical-stage pipeline across inflammatory bowel disease, rheumatic diseases and hidradenitis suppurativa. Multiple proof-of-concept readouts could broaden the opportunity, while its cash balance... Full story

Yahoo Finance • 2 months ago

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

Spyre Therapeutics SYRE expanded its inflammatory-disease strategy in August with SPY772 and the phase II SKYLIGHT study in hidradenitis suppurativa, or HS. The move takes its combination approach into a new disease area beyond inflammator... Full story

Yahoo Finance • 2 months ago

SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?

Spyre Therapeutics SYRE has advanced 44.9% in the past three months, far outpacing the Zacks sub-industry's 11.7% gain and the S&P 500's 1.2% rise. That run has put the durability of the stock's momentum in focus. Positive ulcerative coli... Full story

Yahoo Finance • 3 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in i... Full story

Yahoo Finance • 3 months ago

Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know

Key Points The CEO sold 15,000 shares for $1.4 million on August 3, 2026. This disposition reduced the executive's direct equity position by 3%. The transaction was executed under a Rule 10b5-1 trading plan established on June 20, 2025.10... Full story

Yahoo Finance • 3 months ago

Spyre Therapeutics Non-GAAP EPS of -$0.36 beats by $0.39

* Spyre Therapeutics press release [https://seekingalpha.com/pr/20606776-spyre-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate] (SYRE [https://seekingalpha.com/symbol/SYRE]): Q2 Non-GAAP EPS of -$0.36 be... Full story

Yahoo Finance • 5 months ago

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange... Full story

Yahoo Finance • 5 months ago

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, Hi... Full story

Yahoo Finance • 5 months ago

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing da... Full story

Yahoo Finance • 6 months ago

Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30.... Full story

Yahoo Finance • 6 months ago

Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?

Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the small-cap stocks that are on fire right now. On April 16, Spyre Therapeutics successfully closed an underwritten public offering, generating ~$463.5 million in gross proceeds. The final t... Full story

Yahoo Finance • 6 months ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • 7 months ago

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story